Angiogenesis and angiogenic factor expression in thyroid cancer

Journal of B.U.ON.

Volumn 15, Issue 2, 2010, Pages 357-361

  Giatromanolaki, Alexandra ^a   Lyberakidis, G ^a   Lyratzopoulos, N ^a   Koukourakis, M I ^a   Sivridis, E ^a   Manolas, C ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Angiogenesis; bFGF; Thyroid cancer; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; FEMALE; FOLLICULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROIDECTOMY;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 77954397100     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104: 947-953.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428. (Pubitemid 24345593)
3. Vini L, Hyer SL, Marshall J et al. Long-term results in elderly patients with differentiated thyroid carcinoma. Cancer 2003; 97: 2736-2742. (Pubitemid 36605140)
4. Karavitaki N, Vlassopoulou V, Tzanela M et al. Recurrent and/or metastatic thyroid cancer therapeutic options. Expert Opin Pharmacother 2002; 3: 939-947. (Pubitemid 34752511)
5. Hochster HS. Bevacizumab in combination with chemotherapy first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 2006; 33: S8-14.
6. Scott LJ. Bevacizumab in first-line treatment of metastatic breast cancer. Drugs 2007; 67: 1793-1799. (Pubitemid 47263182)
7. Bauer AJ, Terrell R, Doniparthi NK et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 2002; 12: 953-961. (Pubitemid 35404129)
8. Schoenberger J, Grimm D, Kossmehl P et al. Effects of PTK787/ZK222584 a tyrosine kinase inhibitor on the growth of a poorly differentiated thyroid carcinoma; an animal study. Endocrinology 2004; 145: 1031-1038. (Pubitemid 38280976)
9. Stabenow E, Tavares MR, Ab'Saber AM et al. Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma. Clinics 2005; 60: 233-240.
10. Kilicarslan AB, Ogus M, Arici C et al. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. APMIS 2003; 111: 439-443. (Pubitemid 36560544)
11. Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 2001; 25: 302-306. (Pubitemid 32410370)
12. Parums DV, Cordell JL, Micklem K et al. JC70 a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-757. (Pubitemid 20279705)
13. Turley H, Scott PA, Watts VM et al. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 1998; 186: 313-318. (Pubitemid 28494361)
14. Fontanini G, Vignati S, Pacini F et al. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol 1996; 9: 636-641. (Pubitemid 26227564)
15. Klein M, Picard E, Vignaud JM et al. Vascular endothelial growth factor gene and protein strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 1999; 161: 41-49. (Pubitemid 29170190)
16. Katoh R, Miyagi E, Kawaoi A et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 1999; 30: 891-897. (Pubitemid 29380511)
17. Bunone G, Vigneri P, Mariani L et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999; 155: 1967-1976.
18. Jebreel A, England J, Bedford K et al. Vascular endothelial growth factor (VEGF) receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol 2007; 88: 271-277. (Pubitemid 47256303)
19. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25. (Pubitemid 27076453)
20. Daa T, Kodama M, Kashima K et al. Identification of basic fibroblast growth factor in papillary carcinoma of the thyroid. Acta Pathol Jpn 1993; 43: 582-589. (Pubitemid 23303516)